On Monday Stifel GMP released their 2021 US Cannabis outlook. Andrew Partheniou, Stifel GMP’s cannabis analyst, headlines the note by saying that the US Cannabis regulator arbitrage is a gift for investors. Partheniou, in his first paragraph, writes that they are impressed with how well these companies have built their operations up during 2020 while … Continue reading Stifel: Comparing US Cannabis To Traditional CPG Suggests ~20x Upside